Trial Profile
A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Intepirdine (Primary)
- Indications Dementia; Lewy body disease
- Focus Adverse reactions
- Acronyms HEADWAY-DLB Extension
- Sponsors Sio Gene Therapies [CEASED]
- 10 Apr 2022 This trial has been completed in Spain (Global end date: 09-02-2018), according to European Clinical Trials Database record.
- 06 Apr 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 13 Feb 2018 Status changed from recruiting to discontinued.